Related Experiment Video

Updated: Nov 4, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.1K

PI3Kα targeting, nipping pancreatic cancer evolution in the bud

Glancis Luzeena Raja Arul1,2, Martin E Fernandez-Zapico1

  • 1Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN, USA.

EMBO Molecular Medicine
|May 31, 2021
PubMed

Insights

Researchers identified phosphatidylinositol 3-kinase alpha (PI3Kα) as a key regulator in pancreatic ductal adenocarcinoma (PDAC) metastasis. This signaling pathway influences both tumor spread and the immune response, promoting cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis.
  • Metastasis is a complex process involving multiple signaling pathways.
  • The tumor microenvironment, including immune cells, plays a critical role in cancer progression.

Purpose of the Study:

  • To elucidate key signaling events mediating metastatic evolution in PDAC.
  • To investigate the role of PI3Kα in regulating macro-metastatic disease.
  • To understand the impact of PI3Kα on the pro-tumoural immune response in PDAC.

Main Methods:

  • Utilized a combination of in vitro and in vivo models of PDAC.
  • Employed molecular biology techniques to assess PI3Kα signaling.
  • Analyzed immune cell infiltration and function within the tumor microenvironment.

Main Results:

  • Demonstrated a significant role of PI3Kα in the regulation of macro-metastatic disease in PDAC.
  • Showed that PI3Kα activity correlates with a pro-tumoural immune response.
  • Identified specific immune cell populations modulated by PI3Kα signaling.

Conclusions:

  • PI3Kα is a critical mediator of metastatic evolution in pancreatic cancer.
  • Targeting PI3Kα may offer a therapeutic strategy to inhibit PDAC metastasis.
  • Modulating the immune response via PI3Kα could enhance anti-cancer therapies.

More Related Videos

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

3.2K
Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models03:42

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models

Published on: September 27, 2024

1.7K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K